Obesity is a global health problem, according to data from the Ministry of Health, in Mexico, 70% of Mexicans are overweight and almost a third are obese. But a new drug could put an end to this health problem.
Being overweight and suffering is a major cause of diabetes, cardiovascular disease, bone and muscle disease and some types of cancer.
A new drug could end the obesity problem
It’s a new trend among money-conscious people and it seems that just one injection a week of a new drug could reduce weight.
Weight loss treatments have been around for a long time and are clearly ineffective and questionable. Now, however, a new class of drugs called glp 1 receptor agonists seems to be working.
Semaglutide, developed by Novo Nordisk, a Danish pharmaceutical company, has been shown in clinical trials to lead to weight loss.
(Photo: Special)
The drug is already on sale in some countries
It is already sold under the Govyi brand in the United States, Denmark and Norway, and will soon be available in other countries; Ozempic is a lower-dose version of a diabetes medication that is also used “off-label” for weight loss. A rival drug, glp1, made by Eli Lilly, an American company, was introduced on sale later this year and is even more effective. I guessed.
A drug that has become popular
It is estimated that the market for the drug glp1 could reach 150 billion by 2031, not far from the market for cancer drugs. Some think it can be done like beta blockers or common statins.
about the necessary medicine
Medicines could not have come at a better time. In 2020, two-fifths of the world’s population were overweight or obese. By 2035, says the World Obesity Federation, that figure could rise to more than half, with 4 billion people being overweight or obese. People everywhere are fat.
Some great pain affects everyone and it is an economic problem too
It affects children in schools and playgrounds very cruelly. It will result in some great pain and a great economy more broadly.
According to an academic model, the annual cost to the world economy could reach 4 trillion by 2035 (2.9% of world GDP, compared to 2.2% in 2019). That includes both health care spending and lost work time due to major illnesses and premature deaths.
How do anti-obesity medications work?
There is a big case for new pain medications after diabetic treatments designed to cause weight loss were found.
Semaglutide mimics the release of hormones that stimulate feelings of fullness and decreased appetite. They also decrease the powerful desire to eat, which is hidden inside the brain.
It is not yet known if these drugs can have a long-term effect
The long-term follow-up that this medicine might lead to healing is not yet known. For the lower dosage forms prescribed for diabetes, the side effects, such as vomiting and diarrhea, are mild.
An expensive treatment at the time
In the United States, Wegovy’s billing is about $1,000 per month; to Ozempic around 900. From these prices the prescribed life seems prohibitively expensive. However, a longer perspective is more encouraging.
Over time, companies can negotiate agreements with governments and health care providers to cover the entire population, providing large volumes for low cost. A profitable prospect is already attracting competition and stimulating innovation.
Amgen, AstraZeneca and Pfizer are working on rival drugs; Novo Nordisk has a complete portfolio of the following drugs. Furthermore, even before that, patents will expire, despite the development of lower-cost types.
Undoubtedly, this medicine fills people with obesity with hope, however, there is still time left before it can be accessible to everyone, so it is important that people try to lose their weight and lead a healthy life.
